[jyl]

The serious trials of HCQ continue. In addition to the prevention trial I mentioned before, there is a French randomized trial comparing remdesivir, hydroxychloroquine, and ritonavir-lopinavir "head to head". This trial was supposed to enroll 3000 patients, is only at 700, had another interim analysis this week, review committee decided to continue the trial.

Trial design provided that committee would stop an arm if the interim analysis showed it was clearly inferior to the others. Which suggests that none of the three arms is clearly inferior to the others. That could mean that none are showing strong efficacy. Ritonavir-lopinavir already failed in a randomized controlled trial.